Drbio,
I appreciate your update on Response Biomedical.
Another program that I think adds to the potential value of RBM is flu testing, especially if its sensitivity for avian flu pans out as a way to distinguish itself from the competition. As far as I know, progress in flu testing won't necessarily be part of the 3M collaboration and so deserves separate mention.9/i]
You are right about flu testing but it can't be a catalyst for this year because they didn't sign up the IRB's in time so the test won't be available this year
It is possible if their avian flu test work out that could be important for this year
Market Data 
Markets 
AI
